Education
About Us
Working with TipRanks
Follow Us
Precigen (PGEN)
NASDAQ:PGEN
PGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $2.17
Previous CloseN/A
Volume729.99K
Average Volume (3M)1.96M
Market Cap
$532.22M
Enterprise Value$263.82M
Total Cash (Recent Filing)$102.77M
Total Debt (Recent Filing)$212.26M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
May 07, 2025EPS Estimate
-0.08Last Dividend Ex-Date
Jan 19, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding294,042,970
10 Day Avg. Volume1,300,842
30 Day Avg. Volume1,956,952
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)194.60
Price to Cash Flow (P/CF)-16.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.49K
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$6.25Price Target Upside245.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Precigen News
PremiumCompany Announcements
Precigen’s Earnings Call: Positive Outlook Amid Challenges
PremiumCompany Announcements
Precigen Reports Progress and Financial Results for 2024---
Bulls Say, Bears Say
Bulls Say
Drug Approval ProcessThe FDA grants PRGN-2012 priority review, setting up a PDUFA date, indicating a faster-than-usual review process for the drug.
Market PotentialCommercial launch preparations for PRGN-2012 have been ongoing, indicating strong confidence in the product's market potential.
Partnerships And CollaborationsThe company is working with Eversana, an expert in commercialization of rare disease therapies, for the launch of PRGN-2012.
Bears Say
Earnings MissPrecigen reported earnings that missed consensus estimates, showing a net loss per share slightly higher than expected.
Financial PerformanceFor FY24, Precigen reported total revenue of $3.9M and a net loss of $0.47 per share, compared to the consensus estimated revenue of $4.1M and a net loss of 0.46 per share.
---
Ownership Overview
42.78% Insiders
12.73% Mutual Funds
12.65% Other Institutional Investors
26.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PGEN FAQ
What was Precigen’s price range in the past 12 months?
Precigen lowest stock price was $0.65 and its highest was $2.17 in the past 12 months.
What is Precigen’s market cap?
Precigen’s market cap is $532.22M.
When is Precigen’s upcoming earnings report date?
Precigen’s upcoming earnings report date is May 07, 2025 which is in 44 days.
How were Precigen’s earnings last quarter?
Precigen released its earnings results on Mar 19, 2025. The company reported -$0.074 earnings per share for the quarter, missing the consensus estimate of -$0.052 by -$0.022.
Is Precigen overvalued?
According to Wall Street analysts Precigen’s price is currently Undervalued.
Does Precigen pay dividends?
Precigen pays a Notavailable dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Precigen dividends here
What is Precigen’s EPS estimate?
Precigen’s EPS estimate is -0.08.
How many shares outstanding does Precigen have?
Precigen has 294,042,970 shares outstanding.
What happened to Precigen’s price movement after its last earnings report?
Precigen reported an EPS of -$0.074 in its last earnings report, missing expectations of -$0.052. Following the earnings report the stock price went up 0.559%.
Which hedge fund is a major shareholder of Precigen?
Currently, no hedge funds are holding shares in PGEN
---
Precigen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.25 (245.30% Upside)
$6.25 (245.30% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 13.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.30%
12-Months-Change
Fundamentals
Return on Equity
-136.30%
Trailing 12-Months
Asset Growth
-8.50%
Trailing 12-Months
Company Description
Precigen
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
---
PGEN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook, with significant progress in regulatory approval, commercial readiness, and promising clinical data for multiple programs. Despite an increased net loss and pending confirmatory trials, the positive developments and strategic readiness for PRGN-2012's launch overshadowed the lowlights.Read More>---
PGEN Stock 12 Month Forecast
Average Price Target
$6.25
▲(245.30% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering PGEN
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+12.71%
reiterated a buy rating 5 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +12.71% per trade.
---